ArticleFrontiers in medicine2026
Longitudinal trajectories of hematological indices and serum metalloproteinases-2 and 9 over 1 year after moderate and severe COVID-19.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04961255 (Effects of Post-COVID-19 on Neural Activation and Architecture of the Quadriceps Femoral Muscle-tendon Unit and Its Correlation With Inflammatory Markers), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Post-COVID-19 on Neural Activation and Architecture of the Quadriceps Femoral Muscle-tendon Unit and Its Correlation With Inflammatory Markers
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The long-term clinical burden of Coronavirus disease (COVID-19) remains substantial, yet one-year cohort evidence linking blood-based biomarkers to persistent sequelae is limited. Methods: We conducted a longitudinal study in adults aged 18-80 years who were classified as moderate or severe COVID-19 or non-COVID-19 controls. Blood was collected at four time points through 360 days after infection or hospital discharge. Cytokines were quantified by flow cytometry. MMP-2 and MMP-9 levels and activity were assessed by gelatin zymography. Hematological parameters were measured in an accredited clinical laboratory. Longitudinal effects were evaluated using generalized estimating equations. Results: Compared with moderate cases and controls, participants who experienced severe acute disease showed persistent immune dysregulation and systemic inflammation at approximately 1 year, with higher concentrations of inflammatory mediators and cytokines and sustained elevations in MMP-2 and MMP-9. Complete blood count-derived indices were also altered over time in severe cases, including the aggregate index of systemic inflammation, the C-reactive protein to lymphocyte ratio, the neutrophil to platelet ratio, and the systemic inflammation response index, together with red cell distribution width, while renal function tests, hepatic enzymes, and muscle injury markers were largely stable across groups. Discussion: These findings delineate a persistent inflammatory and matrix-remodeling signature up to 1 year after severe COVID-19, based on longitudinal biomarker profiles rather than symptom-defined long COVID-19 outcomes. This biomarker panel may help to inform future studies of post-acute risk stratification and targeted interventions, but prospective prognostic validation and clinical endpoint data are still required. Clinical trial registration: https://clinicaltrials.gov/study/NCT04961255?term=NCT04961255&rank=1, NCT04961255.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.